| Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests | Sarah de Crescenzo | 04/08/20 | Boston |
| Inovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers | Sarah de Crescenzo | 04/08/20 | National |
| Sage Restructuring Halves Staff, Turns Focus to Failed Depression Drug | Frank Vinluan | 04/07/20 | Boston |
| Creating Consistent Value in Biotech Without Diluting Stakeholders | Alexis Peyroles | 04/07/20 | National |
| Interactive, Online Xcelerating Life Sciences Boston Event Set for May 13 | Editors | 04/07/20 | Boston |
| Millendo May Restructure After Prader-Willi Drug Fails Pivotal Test | Sarah de Crescenzo | 04/06/20 | Detroit Ann Arbor |
| Menlo’s Itching Drug Racks Up Two More Trial Failures, Program Ends | Frank Vinluan | 04/06/20 | New York |
| GSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months | Frank Vinluan | 04/06/20 | San Francisco |
| Xconomy Releases Coronavirus Special Report on Containing the Pandemic Through Innovation & Investment | Editors | 04/06/20 | Boston |
| Dynacure Adds $55M As RNA-Targeted Muscle Disorder Drug Enters Clinic | Sarah de Crescenzo | 04/03/20 | Boston |
| Fate Inks $100M Deal With Janssen for Stem Cell-Derived Cancer Therapies | Sarah de Crescenzo | 04/03/20 | San Diego |
| Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials | Frank Vinluan | 04/03/20 | New York |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| VenBio Partners Bags $394M to Back More Medicine-Making Biotechs | Sarah de Crescenzo | 04/03/20 | Boston |
| Flagship Adds $1.1B for New Meds, More AI, & “Health Security” | Sarah de Crescenzo | 04/02/20 | National |
| Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID | Sarah de Crescenzo | 04/02/20 | National |
| Iteos Therapeutics Adds $125M to Advance Next-Gen Immunotherapies | Sarah de Crescenzo | 04/02/20 | Boston |
| Vir Advances Antibodies Against COVID-19, CEO Leads BIO’s Coronavirus Outreach | Mandy Jackson | 04/02/20 | National |
| Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic | Sarah de Crescenzo | 04/01/20 | San Diego |
| Pandion Pulls In $80M as Ulcerative Colitis Drug Advances in Clinic | Frank Vinluan | 04/01/20 | Boston |
| Aptinyx Moves Ahead With PTSD Therapy Study, Pauses 3 Other Trials | Sarah de Crescenzo | 03/31/20 | National |
| A Baby’s Milestones and the Next Steps for Novartis in Gene Therapy | Frank Vinluan | 03/31/20 | Raleigh Durham |
| Tapping Into the Innovation Grid: J&J, Data, and a Shifting Healthcare Focus | Dan Stanton | 03/31/20 | Europe |
| Biohaven’s Acute Migraine Drug Bests Placebo in Prevention Study | Sarah de Crescenzo | 03/30/20 | National |
| Axsome Plans to Try Again After Failure in Treatment-Resistant Depression | Frank Vinluan | 03/30/20 | New York |
| San Diego Biotech Entrepreneurs, Innovation Lead to “Maturing” Ecosystem | Sarah de Crescenzo | 03/30/20 | San Diego |
| Sanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance | Frank Vinluan | 03/27/20 | Europe |
| Equillium Continues Graft-Versus-Host Disease Trial, Pauses 2 Others | Sarah de Crescenzo | 03/27/20 | San Diego |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections | Sarah de Crescenzo | 03/26/20 | San Diego |
